← Eichor
Study identifier: NCT05836207 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Rewards for Cannabis Abstinence-study

Condition: Cannabis Use Disorder  ·  Sponsor: Parnassia Addiction Research Centre

PhaseNA
Planned participants154
Who can joinAll sexes, 16 Years to 22 Years
Healthy volunteersNo

About this study

The goal of this clinical trial is to investigate the (cost-)effectiveness of contingency management (CM) compared with Cognitive Behavioural Therapy (CBT) for the treatment of cannabis use disorder (CUD) in youth (16-22 years). The main questions it aims to answer are: * What is the efficacy of 12 weeks outpatient CM versus CBT in youths with a CUD, in terms of cannabis abstinence during the intervention period? * What is the long-term efficacy of CM versus CBT at 6- and 12-months follow-up (FU)? * What is the cost-effectiveness of CM versus CBT at 12-months FU from a societal perspective? Study hypotheses are: 1\. CM will result in more cannabis-abstinent days than CBT during the intervention; 2. CM is more effective and cost-effective than CBT at 12 months follow-up. Eligible patients (n=154) will be randomly assigned to either 12 weeks of outpatient CM or CBT. Assessments are conducted by trained research-assistants at baseline, after 6, 12, 26 and 52 weeks, and twice-weekly during treatment and consist of questionnaires, a computer task and collection of urine samples. Primary endpoint is the number of biochemically verified cannabis abstinent days in the 12-week treatment period. Key secondary endpoint: Treatment response: 50% or more reduction in cannabis use days in the past 4 weeks, compared with baseline. The primary outcome will be modelled in the intention-to-treat population in a (negative binomial) regression analysis with treatment group as independent va…

This description comes directly from the study's public registry record.

Talk to the study team

Eva Garssen, MsC  ·  +3188 358 20 34  ·  e.garssen@brijder.nl

Renske Spijkerman, PhD  ·  +31630661532  ·  renske.spijkerman@brijder.nl

Always discuss trial participation with your own doctor first.

Locations (5)

Jellinek, Stichting Arkin B.V.Amsterdam, NetherlandsRecruiting
IrisZorgArnhem, NetherlandsRecruiting
Antes YouzRotterdam, NetherlandsRecruiting
BrijderThe Hague, NetherlandsRecruiting
Novadic-KentronVught, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05836207